Media stories about Uroplasty (NYSE:UPI) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Uroplasty earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the medical device company an impact score of 44.6329306938322 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

COPYRIGHT VIOLATION WARNING: “Uroplasty (UPI) Receives News Impact Score of 0.19” was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/uroplasty-upi-receives-news-impact-score-of-0-19/1528200.html.

Uroplasty Company Profile

Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.

Insider Buying and Selling by Quarter for Uroplasty (NYSE:UPI)

Receive News & Ratings for Uroplasty Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.